| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myotonic Dystrophy | 16 | 2022 | 19 | 5.010 |
Why?
|
| Defibrillators, Implantable | 18 | 2014 | 329 | 3.370 |
Why?
|
| Arrhythmias, Cardiac | 16 | 2022 | 239 | 2.800 |
Why?
|
| Heart Arrest | 10 | 2006 | 113 | 1.460 |
Why?
|
| Muscular Dystrophies | 3 | 2015 | 17 | 1.280 |
Why?
|
| Pacemaker, Artificial | 9 | 2015 | 157 | 1.180 |
Why?
|
| Electric Countershock | 10 | 2006 | 130 | 1.180 |
Why?
|
| Electrocardiography | 10 | 2017 | 601 | 1.150 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 2012 | 174 | 1.050 |
Why?
|
| Anti-Arrhythmia Agents | 6 | 2011 | 98 | 0.870 |
Why?
|
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2022 | 2 | 0.830 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2022 | 2 | 0.830 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2014 | 141 | 0.810 |
Why?
|
| Emergency Medical Services | 9 | 2006 | 225 | 0.750 |
Why?
|
| Sodium Channel Blockers | 2 | 2011 | 23 | 0.730 |
Why?
|
| Tachycardia, Ventricular | 8 | 2017 | 153 | 0.640 |
Why?
|
| Guanine | 2 | 2011 | 21 | 0.610 |
Why?
|
| Single-Blind Method | 1 | 2018 | 249 | 0.590 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 260 | 0.590 |
Why?
|
| Heart | 9 | 2017 | 850 | 0.580 |
Why?
|
| Volunteers | 4 | 2006 | 30 | 0.550 |
Why?
|
| Ventricular Fibrillation | 8 | 2011 | 85 | 0.550 |
Why?
|
| Humans | 59 | 2022 | 68618 | 0.540 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2020 | 277 | 0.510 |
Why?
|
| Heart Failure | 7 | 2020 | 1180 | 0.500 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 5 | 2012 | 61 | 0.500 |
Why?
|
| Trinucleotide Repeats | 3 | 2005 | 8 | 0.500 |
Why?
|
| Police | 4 | 2002 | 34 | 0.500 |
Why?
|
| Heart Diseases | 2 | 2010 | 276 | 0.490 |
Why?
|
| Trinucleotide Repeat Expansion | 2 | 2011 | 5 | 0.440 |
Why?
|
| Advanced Cardiac Life Support | 2 | 2003 | 22 | 0.430 |
Why?
|
| Executive Function | 1 | 2013 | 106 | 0.420 |
Why?
|
| Male | 37 | 2017 | 37321 | 0.420 |
Why?
|
| Electromagnetic Fields | 2 | 2005 | 66 | 0.420 |
Why?
|
| Defibrillators | 3 | 2006 | 11 | 0.420 |
Why?
|
| Cardiopulmonary Resuscitation | 6 | 2006 | 72 | 0.410 |
Why?
|
| Equipment Reuse | 1 | 2011 | 7 | 0.410 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 213 | 0.410 |
Why?
|
| Cardiomyopathies | 2 | 2005 | 167 | 0.400 |
Why?
|
| Memory | 1 | 2013 | 214 | 0.400 |
Why?
|
| Nursing Care | 1 | 2011 | 18 | 0.390 |
Why?
|
| Thymine | 1 | 2011 | 3 | 0.390 |
Why?
|
| Propofol | 1 | 2011 | 36 | 0.390 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 85 | 0.390 |
Why?
|
| Cytosine | 1 | 2011 | 12 | 0.390 |
Why?
|
| Myocardial Ischemia | 3 | 2007 | 172 | 0.390 |
Why?
|
| Mexiletine | 1 | 2011 | 1 | 0.380 |
Why?
|
| Conscious Sedation | 1 | 2011 | 61 | 0.380 |
Why?
|
| Equipment Failure | 3 | 2007 | 112 | 0.370 |
Why?
|
| Heart Failure, Systolic | 1 | 2010 | 16 | 0.370 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 83 | 0.370 |
Why?
|
| Public Sector | 3 | 2006 | 19 | 0.360 |
Why?
|
| Heart Ventricles | 7 | 2007 | 738 | 0.360 |
Why?
|
| Prospective Studies | 8 | 2018 | 3705 | 0.350 |
Why?
|
| Follow-Up Studies | 9 | 2014 | 3259 | 0.350 |
Why?
|
| Cognition | 1 | 2013 | 513 | 0.340 |
Why?
|
| Middle Aged | 24 | 2015 | 21147 | 0.340 |
Why?
|
| Internal-External Control | 1 | 2009 | 60 | 0.340 |
Why?
|
| Female | 30 | 2017 | 38074 | 0.330 |
Why?
|
| Heart Conduction System | 5 | 2005 | 119 | 0.320 |
Why?
|
| Aged | 18 | 2015 | 14862 | 0.320 |
Why?
|
| Physical Fitness | 1 | 2009 | 117 | 0.320 |
Why?
|
| Atrial Fibrillation | 2 | 2018 | 249 | 0.320 |
Why?
|
| Adult | 20 | 2015 | 21403 | 0.310 |
Why?
|
| Myocardium | 7 | 2007 | 1204 | 0.310 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 319 | 0.300 |
Why?
|
| Electrodes | 1 | 2007 | 147 | 0.280 |
Why?
|
| Attitude to Health | 1 | 2009 | 403 | 0.270 |
Why?
|
| Piperidines | 2 | 1997 | 123 | 0.270 |
Why?
|
| Stroke Volume | 3 | 2014 | 586 | 0.260 |
Why?
|
| Equipment Safety | 1 | 2005 | 50 | 0.260 |
Why?
|
| Cell Phone | 1 | 2005 | 44 | 0.250 |
Why?
|
| Neuromuscular Diseases | 1 | 2004 | 14 | 0.240 |
Why?
|
| Heart Function Tests | 1 | 2004 | 33 | 0.240 |
Why?
|
| Pyridines | 2 | 1997 | 261 | 0.240 |
Why?
|
| Cardiac Conduction System Disease | 2 | 2021 | 11 | 0.230 |
Why?
|
| Heart Rate | 4 | 2005 | 568 | 0.230 |
Why?
|
| Amiodarone | 2 | 2003 | 21 | 0.230 |
Why?
|
| Pyrimidine Dimers | 1 | 2003 | 1 | 0.230 |
Why?
|
| Data Collection | 2 | 2004 | 420 | 0.220 |
Why?
|
| Echocardiography | 2 | 2005 | 515 | 0.210 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2015 | 106 | 0.200 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 396 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 504 | 0.200 |
Why?
|
| Imidazoles | 3 | 1997 | 175 | 0.200 |
Why?
|
| Myocardial Infarction | 6 | 2017 | 807 | 0.190 |
Why?
|
| Survival Rate | 4 | 2014 | 1056 | 0.190 |
Why?
|
| Incidence | 3 | 2018 | 1603 | 0.180 |
Why?
|
| Action Potentials | 3 | 1997 | 223 | 0.180 |
Why?
|
| Age Factors | 4 | 2009 | 1864 | 0.180 |
Why?
|
| Imidazolidines | 2 | 1997 | 4 | 0.180 |
Why?
|
| Cardiologists | 1 | 2020 | 9 | 0.180 |
Why?
|
| Theft | 1 | 1999 | 2 | 0.170 |
Why?
|
| Time Factors | 6 | 2013 | 4655 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 468 | 0.170 |
Why?
|
| Prognosis | 4 | 2020 | 2093 | 0.170 |
Why?
|
| Piperazines | 2 | 1997 | 206 | 0.160 |
Why?
|
| Positron-Emission Tomography | 4 | 2007 | 160 | 0.150 |
Why?
|
| Radiopharmaceuticals | 3 | 2007 | 114 | 0.150 |
Why?
|
| Adolescent | 7 | 2011 | 8912 | 0.150 |
Why?
|
| Hemicholinium 3 | 2 | 2007 | 3 | 0.140 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2017 | 73 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 1996 | 14 | 0.140 |
Why?
|
| Community Health Services | 3 | 2006 | 141 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2002 | 767 | 0.140 |
Why?
|
| Hypotonic Solutions | 1 | 1996 | 4 | 0.140 |
Why?
|
| Brugada Syndrome | 1 | 2015 | 5 | 0.130 |
Why?
|
| Sick Sinus Syndrome | 1 | 2015 | 18 | 0.130 |
Why?
|
| Confidence Intervals | 3 | 2014 | 242 | 0.130 |
Why?
|
| Indiana | 3 | 2014 | 35 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 68 | 0.130 |
Why?
|
| Acetylcholinesterase | 2 | 2005 | 19 | 0.130 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2015 | 20 | 0.130 |
Why?
|
| Papillary Muscles | 1 | 1995 | 30 | 0.130 |
Why?
|
| Sotalol | 1 | 1995 | 6 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 208 | 0.120 |
Why?
|
| Isoproterenol | 1 | 1995 | 163 | 0.120 |
Why?
|
| Genetic Variation | 1 | 2015 | 220 | 0.120 |
Why?
|
| Disease Progression | 2 | 2010 | 1038 | 0.120 |
Why?
|
| Registries | 3 | 2015 | 733 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2009 | 737 | 0.120 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2003 | 34 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 786 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2003 | 1046 | 0.120 |
Why?
|
| Genetic Markers | 2 | 2005 | 144 | 0.120 |
Why?
|
| Guinea Pigs | 5 | 1997 | 124 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1995 | 189 | 0.110 |
Why?
|
| Genotype | 2 | 2015 | 786 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2003 | 714 | 0.110 |
Why?
|
| United States | 7 | 2010 | 7367 | 0.110 |
Why?
|
| First Aid | 2 | 2003 | 8 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2014 | 115 | 0.110 |
Why?
|
| Phenotype | 2 | 2015 | 947 | 0.110 |
Why?
|
| Potassium Channels | 4 | 1997 | 55 | 0.110 |
Why?
|
| Carbon Radioisotopes | 3 | 2007 | 34 | 0.100 |
Why?
|
| Animals | 18 | 2015 | 20881 | 0.100 |
Why?
|
| Probability | 2 | 2003 | 245 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2011 | 2358 | 0.100 |
Why?
|
| Risk Factors | 3 | 2014 | 5731 | 0.100 |
Why?
|
| Anesthetics, Intravenous | 1 | 2011 | 27 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2009 | 2800 | 0.100 |
Why?
|
| Canada | 3 | 2006 | 267 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2014 | 383 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2012 | 159 | 0.090 |
Why?
|
| Hypotension | 1 | 2011 | 74 | 0.090 |
Why?
|
| Contraindications | 1 | 2011 | 52 | 0.090 |
Why?
|
| Electric Stimulation | 2 | 2005 | 218 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 76 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2005 | 7029 | 0.090 |
Why?
|
| Urban Population | 2 | 2002 | 255 | 0.090 |
Why?
|
| Fluorine Radioisotopes | 2 | 2007 | 13 | 0.090 |
Why?
|
| Exercise Test | 2 | 2009 | 242 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2009 | 24 | 0.090 |
Why?
|
| Rural Population | 2 | 2005 | 398 | 0.090 |
Why?
|
| Nursing Methodology Research | 1 | 2009 | 39 | 0.090 |
Why?
|
| Dogs | 6 | 2006 | 490 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2020 | 2007 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 107 | 0.080 |
Why?
|
| Quality of Life | 2 | 2009 | 1515 | 0.080 |
Why?
|
| Disease Models, Animal | 6 | 2015 | 2550 | 0.080 |
Why?
|
| Tachycardia | 1 | 2008 | 53 | 0.080 |
Why?
|
| Patch-Clamp Techniques | 3 | 1997 | 204 | 0.070 |
Why?
|
| Electrophysiology | 2 | 2005 | 160 | 0.070 |
Why?
|
| Cause of Death | 1 | 2008 | 241 | 0.070 |
Why?
|
| Computers | 2 | 1984 | 63 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2005 | 57 | 0.070 |
Why?
|
| Cation Transport Proteins | 1 | 2007 | 11 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 1997 | 765 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1040 | 0.070 |
Why?
|
| Choline | 1 | 2006 | 14 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 4848 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2007 | 174 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1054 | 0.070 |
Why?
|
| Clonidine | 1 | 2005 | 66 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2005 | 40 | 0.060 |
Why?
|
| Health Plan Implementation | 1 | 2005 | 37 | 0.060 |
Why?
|
| Myocardial Contraction | 2 | 2004 | 383 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1851 | 0.060 |
Why?
|
| Siblings | 1 | 2005 | 34 | 0.060 |
Why?
|
| Age of Onset | 1 | 2005 | 188 | 0.060 |
Why?
|
| Tomography, Optical | 1 | 2004 | 2 | 0.060 |
Why?
|
| Triage | 1 | 2006 | 109 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2009 | 1330 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2006 | 254 | 0.060 |
Why?
|
| Pyridostigmine Bromide | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2005 | 219 | 0.060 |
Why?
|
| Digestive System Physiological Phenomena | 1 | 1984 | 2 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 365 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 159 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 27 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2005 | 244 | 0.060 |
Why?
|
| Health Policy | 1 | 2006 | 221 | 0.060 |
Why?
|
| Attitude to Death | 1 | 2004 | 52 | 0.060 |
Why?
|
| Education, Continuing | 1 | 2003 | 28 | 0.060 |
Why?
|
| Automation | 1 | 2003 | 45 | 0.060 |
Why?
|
| Self Concept | 1 | 2004 | 132 | 0.060 |
Why?
|
| Autonomic Nervous System | 1 | 2003 | 31 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2003 | 216 | 0.050 |
Why?
|
| Certification | 1 | 2003 | 66 | 0.050 |
Why?
|
| Professional Competence | 1 | 2003 | 100 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 219 | 0.050 |
Why?
|
| Law Enforcement | 1 | 2002 | 10 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 330 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2004 | 237 | 0.050 |
Why?
|
| Sex Factors | 1 | 2005 | 1266 | 0.050 |
Why?
|
| Gambling | 1 | 2001 | 7 | 0.050 |
Why?
|
| Psychometrics | 1 | 2004 | 514 | 0.050 |
Why?
|
| Logistic Models | 1 | 2005 | 1420 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2003 | 880 | 0.050 |
Why?
|
| Membrane Potentials | 3 | 1996 | 200 | 0.050 |
Why?
|
| Aircraft | 1 | 2001 | 30 | 0.050 |
Why?
|
| North America | 1 | 2001 | 112 | 0.050 |
Why?
|
| Heart Massage | 1 | 2000 | 3 | 0.050 |
Why?
|
| Washington | 1 | 2000 | 27 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2000 | 24 | 0.050 |
Why?
|
| Hydantoins | 2 | 1997 | 5 | 0.040 |
Why?
|
| Young Adult | 1 | 2011 | 5717 | 0.040 |
Why?
|
| Myotonin-Protein Kinase | 1 | 1999 | 2 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 546 | 0.040 |
Why?
|
| Catheter Ablation | 2 | 1999 | 229 | 0.040 |
Why?
|
| Prevalence | 1 | 2004 | 1619 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1999 | 106 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 211 | 0.040 |
Why?
|
| Calcium Channels | 2 | 1996 | 59 | 0.040 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 1998 | 12 | 0.040 |
Why?
|
| Atrial Flutter | 1 | 1998 | 16 | 0.040 |
Why?
|
| Rats | 4 | 2007 | 5300 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2014 | 7277 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1753 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 1033 | 0.030 |
Why?
|
| Software | 1 | 1999 | 418 | 0.030 |
Why?
|
| Chloride Channels | 1 | 1996 | 22 | 0.030 |
Why?
|
| Cell Size | 1 | 1996 | 76 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1998 | 313 | 0.030 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 11 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2006 | 282 | 0.030 |
Why?
|
| Respiration Disorders | 1 | 2015 | 20 | 0.030 |
Why?
|
| Blood Pressure | 3 | 2005 | 1451 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 1999 | 1692 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2015 | 38 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1998 | 425 | 0.030 |
Why?
|
| Ventricular Function | 1 | 1995 | 93 | 0.030 |
Why?
|
| Arterio-Arterial Fistula | 1 | 1994 | 4 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 1994 | 32 | 0.030 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 1994 | 12 | 0.030 |
Why?
|
| Mammary Arteries | 1 | 1994 | 18 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1996 | 525 | 0.030 |
Why?
|
| Oocytes | 1 | 1994 | 57 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 202 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 190 | 0.030 |
Why?
|
| Patient Selection | 1 | 1998 | 592 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1140 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Heart-Assist Devices | 1 | 2015 | 221 | 0.030 |
Why?
|
| Child, Preschool | 2 | 1996 | 3187 | 0.020 |
Why?
|
| Adams-Stokes Syndrome | 1 | 1971 | 2 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 1994 | 323 | 0.020 |
Why?
|
| Heart Block | 1 | 1971 | 49 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 848 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 2083 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 481 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1465 | 0.020 |
Why?
|
| Research Design | 2 | 2005 | 729 | 0.020 |
Why?
|
| Program Evaluation | 2 | 2002 | 502 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 2891 | 0.020 |
Why?
|
| Child | 2 | 1996 | 6405 | 0.020 |
Why?
|
| Mice | 1 | 1999 | 8474 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2006 | 109 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 104 | 0.020 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2005 | 7 | 0.020 |
Why?
|
| Butyrylcholinesterase | 1 | 2005 | 9 | 0.020 |
Why?
|
| Gallbladder | 1 | 1985 | 15 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2005 | 18 | 0.020 |
Why?
|
| Glioma | 1 | 2007 | 140 | 0.020 |
Why?
|
| Brain | 2 | 2007 | 2176 | 0.020 |
Why?
|
| Thorax | 1 | 2005 | 49 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 48 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.020 |
Why?
|
| Opossums | 1 | 1984 | 7 | 0.010 |
Why?
|
| Focus Groups | 1 | 2005 | 247 | 0.010 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 58 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2004 | 167 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1027 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 563 | 0.010 |
Why?
|
| Minicomputers | 1 | 1983 | 1 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1985 | 453 | 0.010 |
Why?
|
| Occupational Medicine | 1 | 1983 | 20 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1342 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 658 | 0.010 |
Why?
|
| Local Government | 1 | 2002 | 17 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 652 | 0.010 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2002 | 25 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2005 | 955 | 0.010 |
Why?
|
| Benchmarking | 1 | 2002 | 91 | 0.010 |
Why?
|
| Program Development | 1 | 2002 | 240 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2000 | 100 | 0.010 |
Why?
|
| Bundle of His | 1 | 1999 | 21 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 581 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1999 | 133 | 0.010 |
Why?
|
| Body Surface Potential Mapping | 1 | 1998 | 10 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1995 | 32 | 0.010 |
Why?
|
| Xenopus | 1 | 1994 | 30 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1995 | 314 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1994 | 61 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1994 | 61 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 357 | 0.010 |
Why?
|
| Radiography | 1 | 1994 | 572 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1994 | 742 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 1745 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1994 | 2673 | 0.010 |
Why?
|